It should be 3~5 sections. Company Performance: Zentalis Pharmaceuticals' stock price is heavily influenced by its clinical trial results, especially for its cancer drug candidates. Positive data boosts investor confidence, driving up the price, while negative results can lead to a significant decline.

Market Sentiment: Overall market conditions and investor risk appetite affect ZNTL.US. Broad market downturns or a preference for safer investments can negatively impact the stock, while positive economic news and increased risk tolerance can provide upward momentum.

Regulatory Events: FDA approvals or rejections for Zentalis' drugs are critical price drivers. Approval represents a major milestone, opening market access and revenue streams, leading to stock price increases. Rejections have the opposite effect.

Competition: Progress or setbacks by competitors in the cancer drug market, particularly those developing similar therapies, can impact ZNTL.US. Successful competitive products could reduce Zentalis' market share, while failures could provide an advantage.